SIGA Technologies Inc. is a commercial-stage pharmaceutical company focused on developing and selling antiviral medicines for emerging infectious diseases. Its lead product, TPOXX (tecovirimat), is an antiviral drug approved for the treatment of human smallpox disease caused by variola virus. The company sells oral TPOXX to the U.S. Government and international governments, including through distributors in certain markets, and supplies the intravenous formulation of TPOXX to the U.S. Government. TPOXX is approved by the U.S. Food and Drug Administration, the European Medicines Agency, Health Canada, the UK Medicines and Healthcare Products Regulatory Agency, and the Japanese Pharmaceuticals and Medical Devices Agency. In Europe, the product is marketed as Tecovirimat-SIGA and is indicated for smallpox, cowpox, and vaccinia complications, with regulatory reviews ongoing regarding its indication for mpox. The company maintains a U.S. domestic supply chain for active pharmaceutical ingredients and finished products to mitigate macroeconomic volatility. SIGA holds procurement contracts with the U.S. Biomedical Advanced Research and Development Authority to deliver courses of oral and intravenous TPOXX to the Strategic National Stockpile and to fund post-marketing activities and pediatric formulation development.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage siga.com
Sector Healthcare IR page investor.siga.com/overview/default.aspx
Tags
antivirals, smallpox, orthopoxviruses, government procurement, strategic stockpile, infectious diseases, oral formulation, intravenous formulation, biodefense, TPOXX, tecovirimat, Tecovirimat-SIGA, TEPOXX, IV TPOXX, oral TPOXX
Press page —

Metrics

Valuation  
Market cap $ 244.307M
Market cap (USD) $ 244.307M
P/E 340.00
PEG —
P/BV 1.50
P/S 4.67
P/OCF -21.18
P/FCF 5.67
Dividend yield 2.9%
Turnover / mcap —
Returns  
ROE 11.2%
ROI 52.8%
ROIC 41.2%
Profit margin 24.6%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -11.8%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 9
Quality score -5.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002
Revenue 94.575M 138.719M 139.917M 110.776M 133.67M 124.959M 26.742M 477.054M — — — — — — — — — — — — — — — —
Net profit 23.279M 59.214M 68.069M 33.905M 69.451M 56.342M -7.241M 421.808M -36.235M -39.698M -39.451M -265.463M -17.177M -14.528M 13.594M -28.195M -17.618M -8.599M -5.639M -9.899M -2.288M -9.373M -5.277M —
Free cash flow 43.116M 48.719M 94.778M 41.611M 11.444M — -18.233M 68.769M -8.258M -115.615M 11M 14.148M 57.579M -20.811M 25.337M -11.375M -8.812M -7.538M -6.691M -5.322M -2.254M -5.241M -5.606M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002
Share price 6.11 6.01 5.6 7.36 7.52 7.27 4.77 7.9 4.85 2.9 0.42 1.44 3.27 2.6 2.44 6.49 5.99 3.06 3.38 — — — — —
Price performance 12m 0.02 0.07 -0.24 -0.02 0.03 0.52 -0.4 0.63 0.67 5.94 -0.71 -0.56 0.26 0.07 -0.62 0.08 0.96 -0.09 — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 3.15M 1.8M 1.96M 4.17M 3.34M 83.7M 45.4M 21.1M 21.2M 3.26M
↳ YoY growth -14.2% -42.9% +8.7% +112.7% -19.9% +2,404.3% -45.7% -53.5% +0.2% -84.6%
↳ 5y CAGR +3.6% +13.2% +14.8% +53.3% -1.9% +92.6% +90.7% +60.9% +38.4% -0.5%
Borrowings, current (USD) — — 0.00 80M 0.00 — — — — —
Lease liabilities (USD) — — 0.00 419,709 — — — 564,009 1.35M 795,169
Cash and deposits (USD) 28.7M 19.9M 101M 65.2M 118M 103M 98.8M 150M 155M 155M
Right-of-use assets (USD) — — 2.9M 2.94M 2.94M — — — — —
Net debt (borrowings + leases - cash) (USD) — — -101M 15.2M -118M — — — — —
Cash flow detail
Operating cash flow (USD) -116M -8.16M 68.9M -18.2M 71.5M 11.5M 41.6M 94.8M 48.8M 43.5M
Purchases of property, plant and equipment (USD) -23,927 -100,124 -102,264 -29,094 — — — — — —
Change in receivables (cash effect) (USD) 522,360 1.35M -49,723 -2.21M 827,733 -80.3M 38.2M 24.3M -35,178 17.9M
Change in inventories (cash effect) (USD) -13.8M 22.7M 39.00 -6.74M -8.01M 136,369 -20M -25.5M 15.3M -846,312
Change in payables (cash effect) (USD) -177,342 -1.85M 1.62M 936,839 -2.2M 986,865 2.07M 2M -5.74M -578,641
Dividends paid (cash effect) (USD) — — — — 0.00 0.00 -32.9M -32.1M -42.7M -43.1M
Share buybacks (cash effect) (USD) 0.00 -84,000 0.00 0.00 -28.5M -26M -13M -11.1M 0.00 0.00
Income taxes paid (cash effect) (USD) — — — — — — — -3.5M -30.4M -8.2M
Share-based compensation (USD) 775,541 1.1M 2.27M 2.11M 1.35M 1.27M 1.78M 2.05M 3.64M 3.68M
Operating cash flow before change in receivables (USD) -116M -9.51M 68.9M -16M 70.7M 91.8M 3.37M 70.5M 48.8M 25.6M
Free cash flow (OCF - PPE - intangibles) (USD) -116M -8.26M 68.8M -18.2M — — — — — —
Income detail
Research and development expense (USD) 19.7M 16.7M 13M 13.3M 10.9M 9.94M 22.5M 16.4M 12.3M 20M
↳ 5y CAGR +1.4% -1.7% -1.2% +4.2% -3.6% -12.8% +6.2% +4.8% -1.5% +12.8%
Reported Mar 6, 2018 Mar 6, 2018 Mar 5, 2020 Mar 5, 2020 Mar 2, 2023 Mar 2, 2023 Mar 2, 2023 Mar 10, 2026 Mar 10, 2026 Mar 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

• Awarded $15 Million Procurement Contract from Canadian Department of National Defence for Oral TPOXX in October

• Corporate Update Conference Call Today at 4:30 PM ET

NEW YORK, November 9, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2026.

“While we continue to work with the U.S. Government toward a new TPOXX procurement contract, our international business remains an important part of our strategy,” stated Diem Nguyen, Chief Executive Officer.

October 29, 2026

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Monday, November 9, 2026. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here . Please log in approximately 5-10 minutes prior to the scheduled start time.

Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers.

A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130564. The archived webcast will be available in the Investor Relations section of the Company's website .

About SIGA
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. For more information about SIGA, visit www.siga.com .

October 28, 2026

Continues Canada's commitment to smallpox preparedness for the Canadian Armed Forces

NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that Public Services and Procurement Canada (PSPC) has awarded SIGA a new contract for the procurement of oral TPOXX® (tecovirimat), an antiviral medication used to treat smallpox, on behalf of the Canadian Department of National Defence (CDND) through its Strategic Medical Countermeasures Program. The contract provides for the purchase of up to approximately $15 million by March 31, 2031, of which approximately $9 million represents firm commitments over the first three years of the contract and approximately $6 million is subject to option exercise by the CDND.

This contract is the second contract for TPOXX® awarded by PSPC on behalf of CDND. In April 2020, PSPC awarded a contract for the purchase of up to approximately $14 million of oral TPOXX®, and the final delivery under that contract was made in 2025.

Canada's Defence Industrial Strategy recognizes the importance of maintaining access to critical medical countermeasures as part of Canada's broader health security and defence preparedness objectives. By securing continued access to TPOXX®, this contract helps Canada deliver on that commitment while ensuring that the Canadian Armed Forces have access to an approved medical countermeasure against smallpox.

"Canada has been a consistent leader in smallpox preparedness, and this award reflects its sustained commitment to ensuring its military is ready to respond to a potential outbreak," said Diem Nguyen, Chief Executive Officer. "Canadian Armed Forces members are often among the first called upon in a public health emergency, and ready access to an approved smallpox antiviral helps ensure they can safely and effectively carry out that mission. We are proud to continue supporting Canada and look forward to further strengthening our relationships with other governments around the world as we do our part to help protect populations from smallpox."

Oral TPOXX® was approved by Health Canada for the treatment of smallpox in November 2021.

ABOUT SIGA

SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on smallpox, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. For more information about SIGA, visit www.siga.com .

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements relating to SIGA’s future business development and plans. Forward-looking statements include statements regarding our future financial position, business strategy, budgets, projected costs, plans and objectives of management for future operations, and delivering products to domestic and international customers under procurement contracts. The words “may,” “continue,” “estimate,” “intend,” “plan,” “will,” “believe,” “project,” “expect,” “seek,” “anticipate,” “could,” “should,” “target,” “goal,” “potential” and similar expressions may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. SIGA’s actual results could differ materially from those anticipated by such forward-looking statements due to a number of factors, some of which are beyond SIGA’s control, including, but not limited to, (i) the risk that SIGA is not able to secure in a timely manner new contracts with the U.S. Government to substantially maintain or expand the U.S. Government stockpile of TPOXX®, (ii) the risk that SIGA may not complete remaining performance under the 19C BARDA Contract (the "BARDA Contract"), with the U.S. Biomedical Advanced Research and Development Authority ("BARDA") on schedule or in accordance with contractual terms, (iii) the risk that the nascent international biodefense market does not develop to a degree that allows SIGA to continue to successfully market TPOXX® internationally, (iv) the risk that potential products, including potential alternative uses or formulations of TPOXX® that appear promising to SIGA or its collaborators, cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (v) the risk that target timing for deliveries of product to customers, and the recognition of related revenues, are delayed or adversely impacted by the actions, or inaction, of contract manufacturing organizations, or other vendors, within the supply chain, or due to coordination activities between the customer and supply chain vendors, (vi) the risk that SIGA or its collaborators will not obtain or maintain appropriate or necessary governmental approvals to market these or other potential products or uses, (vii) the risk that any challenge to SIGA’s patent and other property rights, if adversely determined, could affect SIGA’s business and, even if determined favorably, could be costly, (viii) the risk that regulatory requirements applicable to SIGA’s products may result in the need for further or additional testing or documentation that will delay or prevent SIGA from seeking, obtaining or maintaining needed approvals to market these products, (ix) the risk that changes in domestic or foreign economic and market conditions may affect SIGA’s ability to advance its research or may affect its products adversely, (x) the effect of federal, state, and foreign regulation, including drug regulation and international trade regulation, on SIGA’s businesses, (xi) the impacts of significant recent shifts in trade policies, including the imposition of tariffs, retaliatory tariff measures, and subsequent modifications or suspensions thereof, and market reactions to such policies and resulting trade disputes, (xii) the risk of disruptions to SIGA’s supply chain for the manufacture of TPOXX®, causing delays in SIGA’s research and development activities, causing delays or the re-allocation of funding in connection with SIGA’s government contracts, or diverting the attention of government staff overseeing SIGA’s government contracts, (xiii) risks associated with actions or uncertainties surrounding the debt ceiling, or the changes in U.S. political environment, and (xiv) the risk that the U.S. or foreign governments' responses (including inaction) to national or global economic conditions or infectious diseases, are ineffective and may adversely affect SIGA’s business, as well as the risks and uncertainties included in Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025 and SIGA's subsequent filings with the Securities and Exchange Commission. SIGA urges investors and security holders to read those documents free of charge at the SEC's website at http://www.sec.gov. All such forward-looking statements are current only as of the date on which such statements were made. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events. 

Investor and Media Contact
Suzanne Harnett
[email protected]

Primary Logo

Source: SIGA Technologies Inc.

View All News

Prompts

SIGA Technologies Inc. (ticker SIGA), listed in United States.

Company History

Date Change Detail
Sep 28, 2000 Renamed SIGA PHARMACEUTICALS INC → SIGA TECHNOLOGIES INC

ETFs Holding SIGA Technologies Inc.

ETF Weight in ETF Shares Market value As of
MYLD 0.76% 78,417 $ 256.424K Jul 31, 2026
SQLV 0.17% 13,361 $ 48.634K Jun 30, 2026
AFSM 0.06% 29,170 $ 83.135K Nov 16, 2026
FEAC 0.04% 2,980 $ 10.847K Jun 30, 2026
AVUV 0.01% 1,234,464 $ 3.518M Nov 16, 2026
AVSC 0.01% 59,807 $ 170.45K Nov 16, 2026
DFSV 0.00% 355,867 $ 1.028M Nov 12, 2026
DFAT 0.00% 338,348 $ 977.826K Nov 12, 2026
DFAS 0.00% 306,127 $ 884.707K Nov 12, 2026
DXUV 0.00% 43,712 $ 126.328K Nov 12, 2026
DFAC 0.00% 197,309 $ 570.223K Nov 12, 2026
DFAU 0.00% 5,523 $ 15.961K Nov 12, 2026
AVUS 0.00% 20,999 $ 59.847K Nov 16, 2026